These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 31416952)

  • 1. Downgrading of regulation in regenerative medicine.
    Sipp D; Sleeboom-Faulkner M
    Science; 2019 Aug; 365(6454):644-646. PubMed ID: 31416952
    [No Abstract]   [Full Text] [Related]  

  • 2. Regenerative medicine: a snapshot of the current regulatory environment and standards.
    Messenger MP; Tomlins PE
    Adv Mater; 2011 Mar; 23(12):H10-7. PubMed ID: 21433095
    [No Abstract]   [Full Text] [Related]  

  • 3. It's about change...regenerative medicine in the Obama era.
    Klein RN; Doyle J; Siegel B
    Regen Med; 2009 Jan; 4(1):27-32. PubMed ID: 19250058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Balancing Safety and Efficacy With Early Availability in the Regulation of Regenerative Medicine Product.
    Fujiwara Y; Maruyama Y; Honda F
    Clin Pharmacol Ther; 2021 May; 109(5):1182-1185. PubMed ID: 32979224
    [No Abstract]   [Full Text] [Related]  

  • 5. Reimbursement and pricing of regenerative medicine in South Korea: key factors for achieving reimbursement.
    Cho E; Yoo SL; Kang Y; Lee JH
    Regen Med; 2020 Apr; 15(4):1550-1560. PubMed ID: 32356480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rejuvenating Regenerative Medicine Regulation.
    Charo RA; Sipp D
    N Engl J Med; 2018 Feb; 378(6):504-505. PubMed ID: 29320637
    [No Abstract]   [Full Text] [Related]  

  • 7. Balancing Safety and Innovation for Cell-Based Regenerative Medicine.
    Marks P; Gottlieb S
    N Engl J Med; 2018 Mar; 378(10):954-959. PubMed ID: 29514023
    [No Abstract]   [Full Text] [Related]  

  • 8. Regenerative medicine, resource and regulation: lessons learned from the remedi project.
    Ginty PJ; Rayment EA; Hourd P; Williams DJ
    Regen Med; 2011 Mar; 6(2):241-53. PubMed ID: 21391857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cells as drugs?: regulating the future of medicine.
    Pivarnik G
    Am J Law Med; 2014; 40(2-3):298-321. PubMed ID: 25211998
    [No Abstract]   [Full Text] [Related]  

  • 10. The government's role in advancing regenerative medicine and tissue engineering - science, safety, and ethics.
    Smith DS
    Periodontol 2000; 2006; 41():16-29. PubMed ID: 16686924
    [No Abstract]   [Full Text] [Related]  

  • 11. A RAT by Another Name: 21
    Riley MF
    Am J Law Med; 2018 May; 44(2-3):291-308. PubMed ID: 30106653
    [No Abstract]   [Full Text] [Related]  

  • 12. Regenerative medicine 2.0.
    Mason C
    Regen Med; 2007 Jan; 2(1):11-8. PubMed ID: 17465770
    [No Abstract]   [Full Text] [Related]  

  • 13. Industry perceptions of barriers to commercialization of regenerative medicine products in the UK.
    Plagnol AC; Rowley E; Martin P; Livesey F
    Regen Med; 2009 Jul; 4(4):549-59. PubMed ID: 19580404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stem-cell research: after the gold rush.
    Aldhous P
    Nature; 2005 Apr; 434(7034):694-6. PubMed ID: 15815600
    [No Abstract]   [Full Text] [Related]  

  • 15. Is the FDA regulating the practice of medicine?
    Aicher RH
    Aesthet Surg J; 2013 Mar; 33(3):452-5. PubMed ID: 23515389
    [No Abstract]   [Full Text] [Related]  

  • 16. The UK relative to other single payer-dominated healthcare markets for regenerative medicine therapies.
    Rose JB; Williams DJ
    Regen Med; 2012 May; 7(3):429-38. PubMed ID: 22594333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The implications of "advanced therapies" regulation.
    Sethe SC
    Rejuvenation Res; 2010; 13(2-3):327-8. PubMed ID: 20462386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. US FDA outreach to the regenerative medicine community: challenges and opportunities.
    Whittlesey KJ; Witten C
    Regen Med; 2012 Jul; 7(4):595-603. PubMed ID: 22817631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA's claims over stem cells upheld.
    Cyranoski D
    Nature; 2012 Aug; 488(7409):14. PubMed ID: 22859178
    [No Abstract]   [Full Text] [Related]  

  • 20. Intellectual property strategy for regenerative medicine: is it time to 'regenerate'?
    Komatani TS
    Pharm Pat Anal; 2014 Sep; 3(5):475-9. PubMed ID: 25374315
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.